Abstract

The field of oncology has seen significant medicinal advances in recent years, with advanced therapy medicinal products (ATMPs) bringing new promise to the treatment of cancers. Research continues to explore next-generation cell and gene therapies, offering novel and often curative ways to tackle many different cancers and cancer subtypes.

This article assesses some of the most notable clinical developments in recent years, where the next generation of research is likely to be heading in the coming years, how the regulatory authorities are responding to these advances, and how these developments and regulatory proposals are likely to impact patient access.